nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—kidney cancer—lung cancer	0.376	1	CtDrD
Temsirolimus—MTOR—lung cancer	0.213	0.853	CbGaD
Temsirolimus—ABCB1—lung cancer	0.0366	0.147	CbGaD
Temsirolimus—CYP3A5—Gefitinib—lung cancer	0.0115	0.0523	CbGbCtD
Temsirolimus—CYP3A5—Teniposide—lung cancer	0.0111	0.0507	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.00826	0.0377	CbGbCtD
Temsirolimus—CYP3A7—Paclitaxel—lung cancer	0.00826	0.0377	CbGbCtD
Temsirolimus—CYP3A7—Irinotecan—lung cancer	0.00815	0.0372	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.00815	0.0372	CbGbCtD
Temsirolimus—ABCB1—Topotecan—lung cancer	0.00815	0.0372	CbGbCtD
Temsirolimus—ABCB1—Gefitinib—lung cancer	0.00745	0.034	CbGbCtD
Temsirolimus—CYP2D6—Gefitinib—lung cancer	0.00702	0.0321	CbGbCtD
Temsirolimus—CYP3A5—Crizotinib—lung cancer	0.00702	0.032	CbGbCtD
Temsirolimus—CYP3A5—Erlotinib—lung cancer	0.00677	0.0309	CbGbCtD
Temsirolimus—CYP3A5—Paclitaxel—lung cancer	0.0062	0.0283	CbGbCtD
Temsirolimus—CYP3A5—Irinotecan—lung cancer	0.00611	0.0279	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.00597	0.0273	CbGbCtD
Temsirolimus—CYP3A7—Docetaxel—lung cancer	0.00597	0.0273	CbGbCtD
Temsirolimus—ABCB1—Vinorelbine—lung cancer	0.00574	0.0262	CbGbCtD
Temsirolimus—CYP2D6—Vinorelbine—lung cancer	0.00541	0.0247	CbGbCtD
Temsirolimus—CYP3A5—Etoposide—lung cancer	0.0049	0.0224	CbGbCtD
Temsirolimus—CYP3A4—Topotecan—lung cancer	0.00488	0.0223	CbGbCtD
Temsirolimus—ABCB1—Crizotinib—lung cancer	0.00457	0.0208	CbGbCtD
Temsirolimus—CYP3A5—Docetaxel—lung cancer	0.00448	0.0205	CbGbCtD
Temsirolimus—CYP3A4—Gefitinib—lung cancer	0.00447	0.0204	CbGbCtD
Temsirolimus—ABCB1—Gemcitabine—lung cancer	0.00446	0.0204	CbGbCtD
Temsirolimus—ABCB1—Erlotinib—lung cancer	0.00441	0.0201	CbGbCtD
Temsirolimus—CYP3A4—Teniposide—lung cancer	0.00433	0.0198	CbGbCtD
Temsirolimus—CYP2D6—Erlotinib—lung cancer	0.00415	0.019	CbGbCtD
Temsirolimus—ABCB1—Paclitaxel—lung cancer	0.00403	0.0184	CbGbCtD
Temsirolimus—ABCB1—Irinotecan—lung cancer	0.00398	0.0182	CbGbCtD
Temsirolimus—ABCB1—Vinblastine—lung cancer	0.00354	0.0161	CbGbCtD
Temsirolimus—CYP3A4—Vinorelbine—lung cancer	0.00344	0.0157	CbGbCtD
Temsirolimus—CYP2D6—Vinblastine—lung cancer	0.00333	0.0152	CbGbCtD
Temsirolimus—ABCB1—Cisplatin—lung cancer	0.00324	0.0148	CbGbCtD
Temsirolimus—ABCB1—Etoposide—lung cancer	0.00319	0.0145	CbGbCtD
Temsirolimus—ABCB1—Docetaxel—lung cancer	0.00292	0.0133	CbGbCtD
Temsirolimus—CYP3A4—Crizotinib—lung cancer	0.00274	0.0125	CbGbCtD
Temsirolimus—CYP3A4—Erlotinib—lung cancer	0.00264	0.0121	CbGbCtD
Temsirolimus—CYP3A4—Paclitaxel—lung cancer	0.00242	0.011	CbGbCtD
Temsirolimus—CYP3A4—Irinotecan—lung cancer	0.00238	0.0109	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—lung cancer	0.00217	0.00992	CbGbCtD
Temsirolimus—CYP3A4—Vinblastine—lung cancer	0.00212	0.00968	CbGbCtD
Temsirolimus—ABCB1—Methotrexate—lung cancer	0.00211	0.00961	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—lung cancer	0.00205	0.00935	CbGbCtD
Temsirolimus—CYP3A4—Etoposide—lung cancer	0.00191	0.00872	CbGbCtD
Temsirolimus—CYP3A4—Docetaxel—lung cancer	0.00175	0.00798	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—lung cancer	0.0013	0.00595	CbGbCtD
Temsirolimus—MTOR—mammary gland—lung cancer	0.000799	0.119	CbGeAlD
Temsirolimus—Everolimus—MTOR—lung cancer	0.000753	0.286	CrCbGaD
Temsirolimus—Pimecrolimus—MTOR—lung cancer	0.000753	0.286	CrCbGaD
Temsirolimus—FKBP1A—mammary gland—lung cancer	0.000718	0.107	CbGeAlD
Temsirolimus—MTOR—respiratory system—lung cancer	0.000532	0.0792	CbGeAlD
Temsirolimus—FKBP1A—respiratory system—lung cancer	0.000479	0.0713	CbGeAlD
Temsirolimus—Tacrolimus—MTOR—lung cancer	0.000448	0.17	CrCbGaD
Temsirolimus—Sirolimus—MTOR—lung cancer	0.000448	0.17	CrCbGaD
Temsirolimus—MTOR—epithelium—lung cancer	0.000445	0.0662	CbGeAlD
Temsirolimus—FKBP1A—epithelium—lung cancer	0.0004	0.0596	CbGeAlD
Temsirolimus—FKBP1A—bronchus—lung cancer	0.000394	0.0587	CbGeAlD
Temsirolimus—FKBP1A—trachea—lung cancer	0.000354	0.0527	CbGeAlD
Temsirolimus—FKBP1A—cardiac atrium—lung cancer	0.000332	0.0495	CbGeAlD
Temsirolimus—MTOR—bone marrow—lung cancer	0.000312	0.0464	CbGeAlD
Temsirolimus—MTOR—lung—lung cancer	0.000283	0.0421	CbGeAlD
Temsirolimus—FKBP1A—bone marrow—lung cancer	0.000281	0.0418	CbGeAlD
Temsirolimus—FKBP1A—lung—lung cancer	0.000254	0.0378	CbGeAlD
Temsirolimus—CYP3A5—respiratory system—lung cancer	0.000208	0.031	CbGeAlD
Temsirolimus—MTOR—lymph node—lung cancer	0.000193	0.0288	CbGeAlD
Temsirolimus—FKBP1A—lymph node—lung cancer	0.000174	0.0259	CbGeAlD
Temsirolimus—ABCB1—respiratory system—lung cancer	0.000111	0.0165	CbGeAlD
Temsirolimus—CYP3A5—lung—lung cancer	0.000111	0.0165	CbGeAlD
Temsirolimus—ABCB1—epithelium—lung cancer	9.25e-05	0.0138	CbGeAlD
Temsirolimus—ABCB1—trachea—lung cancer	8.18e-05	0.0122	CbGeAlD
Temsirolimus—Tacrolimus—ALB—lung cancer	8.07e-05	0.0306	CrCbGaD
Temsirolimus—Tacrolimus—ABCB1—lung cancer	7.7e-05	0.0292	CrCbGaD
Temsirolimus—Sirolimus—ABCB1—lung cancer	7.7e-05	0.0292	CrCbGaD
Temsirolimus—ABCB1—bone marrow—lung cancer	6.49e-05	0.00966	CbGeAlD
Temsirolimus—ABCB1—lung—lung cancer	5.88e-05	0.00875	CbGeAlD
Temsirolimus—ABCB1—lymph node—lung cancer	4.02e-05	0.00599	CbGeAlD
Temsirolimus—Infestation—Methotrexate—lung cancer	2.79e-05	0.000309	CcSEcCtD
Temsirolimus—Depression—Methotrexate—lung cancer	2.78e-05	0.000308	CcSEcCtD
Temsirolimus—Anorexia—Paclitaxel—lung cancer	2.77e-05	0.000307	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—lung cancer	2.77e-05	0.000307	CcSEcCtD
Temsirolimus—Pain—Cisplatin—lung cancer	2.77e-05	0.000307	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Methotrexate—lung cancer	2.76e-05	0.000306	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—lung cancer	2.76e-05	0.000306	CcSEcCtD
Temsirolimus—Vomiting—Vinorelbine—lung cancer	2.75e-05	0.000305	CcSEcCtD
Temsirolimus—Body temperature increased—Gemcitabine—lung cancer	2.75e-05	0.000305	CcSEcCtD
Temsirolimus—Renal failure—Methotrexate—lung cancer	2.74e-05	0.000304	CcSEcCtD
Temsirolimus—Rash—Vinorelbine—lung cancer	2.73e-05	0.000302	CcSEcCtD
Temsirolimus—Dermatitis—Vinorelbine—lung cancer	2.72e-05	0.000302	CcSEcCtD
Temsirolimus—Abdominal distension—Doxorubicin—lung cancer	2.72e-05	0.000302	CcSEcCtD
Temsirolimus—Stomatitis—Methotrexate—lung cancer	2.72e-05	0.000301	CcSEcCtD
Temsirolimus—Headache—Vinorelbine—lung cancer	2.71e-05	0.0003	CcSEcCtD
Temsirolimus—Conjunctivitis—Methotrexate—lung cancer	2.71e-05	0.0003	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—lung cancer	2.71e-05	0.0003	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—lung cancer	2.71e-05	0.0003	CcSEcCtD
Temsirolimus—Leukopenia—Docetaxel—lung cancer	2.7e-05	0.0003	CcSEcCtD
Temsirolimus—Haematuria—Methotrexate—lung cancer	2.66e-05	0.000295	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Paclitaxel—lung cancer	2.65e-05	0.000294	CcSEcCtD
Temsirolimus—Dyspnoea—Etoposide—lung cancer	2.65e-05	0.000293	CcSEcCtD
Temsirolimus—Somnolence—Etoposide—lung cancer	2.64e-05	0.000292	CcSEcCtD
Temsirolimus—Cough—Docetaxel—lung cancer	2.64e-05	0.000292	CcSEcCtD
Temsirolimus—Insomnia—Paclitaxel—lung cancer	2.63e-05	0.000292	CcSEcCtD
Temsirolimus—Epistaxis—Methotrexate—lung cancer	2.63e-05	0.000291	CcSEcCtD
Temsirolimus—Hypersensitivity—Irinotecan—lung cancer	2.63e-05	0.000291	CcSEcCtD
Temsirolimus—Convulsion—Docetaxel—lung cancer	2.62e-05	0.00029	CcSEcCtD
Temsirolimus—Hypertension—Docetaxel—lung cancer	2.61e-05	0.000289	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—lung cancer	2.6e-05	0.000289	CcSEcCtD
Temsirolimus—Dyspnoea—Paclitaxel—lung cancer	2.59e-05	0.000288	CcSEcCtD
Temsirolimus—Somnolence—Paclitaxel—lung cancer	2.59e-05	0.000287	CcSEcCtD
Temsirolimus—Decreased appetite—Etoposide—lung cancer	2.58e-05	0.000286	CcSEcCtD
Temsirolimus—Chest pain—Docetaxel—lung cancer	2.57e-05	0.000285	CcSEcCtD
Temsirolimus—Arthralgia—Docetaxel—lung cancer	2.57e-05	0.000285	CcSEcCtD
Temsirolimus—Myalgia—Docetaxel—lung cancer	2.57e-05	0.000285	CcSEcCtD
Temsirolimus—Nausea—Vinorelbine—lung cancer	2.57e-05	0.000285	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Etoposide—lung cancer	2.56e-05	0.000284	CcSEcCtD
Temsirolimus—Body temperature increased—Cisplatin—lung cancer	2.56e-05	0.000284	CcSEcCtD
Temsirolimus—Asthenia—Irinotecan—lung cancer	2.56e-05	0.000284	CcSEcCtD
Temsirolimus—Fatigue—Etoposide—lung cancer	2.56e-05	0.000284	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	2.55e-05	0.000283	CcSEcCtD
Temsirolimus—Constipation—Etoposide—lung cancer	2.54e-05	0.000281	CcSEcCtD
Temsirolimus—Pain—Etoposide—lung cancer	2.54e-05	0.000281	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—lung cancer	2.53e-05	0.000281	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—lung cancer	2.53e-05	0.000281	CcSEcCtD
Temsirolimus—Decreased appetite—Paclitaxel—lung cancer	2.53e-05	0.00028	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—lung cancer	2.52e-05	0.000279	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Paclitaxel—lung cancer	2.51e-05	0.000278	CcSEcCtD
Temsirolimus—Fatigue—Paclitaxel—lung cancer	2.51e-05	0.000278	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—lung cancer	2.5e-05	0.000277	CcSEcCtD
Temsirolimus—Asthenia—Gemcitabine—lung cancer	2.49e-05	0.000276	CcSEcCtD
Temsirolimus—Pain—Paclitaxel—lung cancer	2.49e-05	0.000276	CcSEcCtD
Temsirolimus—Constipation—Paclitaxel—lung cancer	2.49e-05	0.000276	CcSEcCtD
Temsirolimus—Pharyngitis—Methotrexate—lung cancer	2.48e-05	0.000275	CcSEcCtD
Temsirolimus—Urinary tract disorder—Methotrexate—lung cancer	2.47e-05	0.000274	CcSEcCtD
Temsirolimus—Anaphylactic shock—Docetaxel—lung cancer	2.47e-05	0.000273	CcSEcCtD
Temsirolimus—Oedema—Docetaxel—lung cancer	2.47e-05	0.000273	CcSEcCtD
Temsirolimus—Pruritus—Gemcitabine—lung cancer	2.46e-05	0.000273	CcSEcCtD
Temsirolimus—Urethral disorder—Methotrexate—lung cancer	2.45e-05	0.000272	CcSEcCtD
Temsirolimus—Infection—Docetaxel—lung cancer	2.45e-05	0.000272	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—lung cancer	2.45e-05	0.000271	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—lung cancer	2.44e-05	0.000271	CcSEcCtD
Temsirolimus—Diarrhoea—Irinotecan—lung cancer	2.44e-05	0.000271	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—lung cancer	2.43e-05	0.000269	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Etoposide—lung cancer	2.43e-05	0.000269	CcSEcCtD
Temsirolimus—Nervous system disorder—Docetaxel—lung cancer	2.42e-05	0.000268	CcSEcCtD
Temsirolimus—Thrombocytopenia—Docetaxel—lung cancer	2.41e-05	0.000268	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—lung cancer	2.41e-05	0.000268	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—lung cancer	2.41e-05	0.000268	CcSEcCtD
Temsirolimus—Skin disorder—Docetaxel—lung cancer	2.4e-05	0.000266	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—lung cancer	2.39e-05	0.000265	CcSEcCtD
Temsirolimus—Hypersensitivity—Cisplatin—lung cancer	2.39e-05	0.000265	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Paclitaxel—lung cancer	2.38e-05	0.000264	CcSEcCtD
Temsirolimus—Diarrhoea—Gemcitabine—lung cancer	2.38e-05	0.000264	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—lung cancer	2.37e-05	0.000263	CcSEcCtD
Temsirolimus—Erythema multiforme—Methotrexate—lung cancer	2.37e-05	0.000262	CcSEcCtD
Temsirolimus—Dizziness—Irinotecan—lung cancer	2.36e-05	0.000262	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—lung cancer	2.35e-05	0.000261	CcSEcCtD
Temsirolimus—Anorexia—Docetaxel—lung cancer	2.35e-05	0.000261	CcSEcCtD
Temsirolimus—Body temperature increased—Etoposide—lung cancer	2.35e-05	0.00026	CcSEcCtD
Temsirolimus—Abdominal pain—Etoposide—lung cancer	2.35e-05	0.00026	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—lung cancer	2.35e-05	0.00026	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—lung cancer	2.35e-05	0.00026	CcSEcCtD
Temsirolimus—Eye disorder—Methotrexate—lung cancer	2.34e-05	0.000259	CcSEcCtD
Temsirolimus—Asthenia—Cisplatin—lung cancer	2.32e-05	0.000258	CcSEcCtD
Temsirolimus—Cardiac disorder—Methotrexate—lung cancer	2.32e-05	0.000257	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—lung cancer	2.3e-05	0.000255	CcSEcCtD
Temsirolimus—Abdominal pain—Paclitaxel—lung cancer	2.3e-05	0.000255	CcSEcCtD
Temsirolimus—Body temperature increased—Paclitaxel—lung cancer	2.3e-05	0.000255	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—lung cancer	2.28e-05	0.000252	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—lung cancer	2.27e-05	0.000252	CcSEcCtD
Temsirolimus—Vomiting—Irinotecan—lung cancer	2.27e-05	0.000251	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—lung cancer	2.26e-05	0.000251	CcSEcCtD
Temsirolimus—Immune system disorder—Methotrexate—lung cancer	2.26e-05	0.000251	CcSEcCtD
Temsirolimus—Mediastinal disorder—Methotrexate—lung cancer	2.25e-05	0.00025	CcSEcCtD
Temsirolimus—Rash—Irinotecan—lung cancer	2.25e-05	0.000249	CcSEcCtD
Temsirolimus—Dermatitis—Irinotecan—lung cancer	2.25e-05	0.000249	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Docetaxel—lung cancer	2.25e-05	0.000249	CcSEcCtD
Temsirolimus—Chills—Methotrexate—lung cancer	2.24e-05	0.000249	CcSEcCtD
Temsirolimus—Headache—Irinotecan—lung cancer	2.23e-05	0.000248	CcSEcCtD
Temsirolimus—Insomnia—Docetaxel—lung cancer	2.23e-05	0.000247	CcSEcCtD
Temsirolimus—Diarrhoea—Cisplatin—lung cancer	2.22e-05	0.000246	CcSEcCtD
Temsirolimus—Vomiting—Gemcitabine—lung cancer	2.21e-05	0.000245	CcSEcCtD
Temsirolimus—Dyspnoea—Docetaxel—lung cancer	2.2e-05	0.000244	CcSEcCtD
Temsirolimus—Somnolence—Docetaxel—lung cancer	2.19e-05	0.000243	CcSEcCtD
Temsirolimus—Mental disorder—Methotrexate—lung cancer	2.19e-05	0.000243	CcSEcCtD
Temsirolimus—Rash—Gemcitabine—lung cancer	2.19e-05	0.000243	CcSEcCtD
Temsirolimus—Dermatitis—Gemcitabine—lung cancer	2.19e-05	0.000243	CcSEcCtD
Temsirolimus—Hypersensitivity—Etoposide—lung cancer	2.19e-05	0.000242	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—lung cancer	2.18e-05	0.000241	CcSEcCtD
Temsirolimus—Malnutrition—Methotrexate—lung cancer	2.18e-05	0.000241	CcSEcCtD
Temsirolimus—Headache—Gemcitabine—lung cancer	2.18e-05	0.000241	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—lung cancer	2.17e-05	0.000241	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—lung cancer	2.15e-05	0.000238	CcSEcCtD
Temsirolimus—Decreased appetite—Docetaxel—lung cancer	2.14e-05	0.000238	CcSEcCtD
Temsirolimus—Hypersensitivity—Paclitaxel—lung cancer	2.14e-05	0.000238	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—lung cancer	2.14e-05	0.000237	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—lung cancer	2.13e-05	0.000237	CcSEcCtD
Temsirolimus—Dysgeusia—Methotrexate—lung cancer	2.13e-05	0.000236	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Docetaxel—lung cancer	2.13e-05	0.000236	CcSEcCtD
Temsirolimus—Asthenia—Etoposide—lung cancer	2.13e-05	0.000236	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—lung cancer	2.13e-05	0.000236	CcSEcCtD
Temsirolimus—Fatigue—Docetaxel—lung cancer	2.13e-05	0.000236	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—lung cancer	2.12e-05	0.000235	CcSEcCtD
Temsirolimus—Nausea—Irinotecan—lung cancer	2.12e-05	0.000235	CcSEcCtD
Temsirolimus—Pain—Docetaxel—lung cancer	2.11e-05	0.000234	CcSEcCtD
Temsirolimus—Constipation—Docetaxel—lung cancer	2.11e-05	0.000234	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—lung cancer	2.11e-05	0.000234	CcSEcCtD
Temsirolimus—Pruritus—Etoposide—lung cancer	2.1e-05	0.000233	CcSEcCtD
Temsirolimus—Asthenia—Paclitaxel—lung cancer	2.09e-05	0.000231	CcSEcCtD
Temsirolimus—Nausea—Gemcitabine—lung cancer	2.06e-05	0.000229	CcSEcCtD
Temsirolimus—Vomiting—Cisplatin—lung cancer	2.06e-05	0.000228	CcSEcCtD
Temsirolimus—Pruritus—Paclitaxel—lung cancer	2.06e-05	0.000228	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—lung cancer	2.05e-05	0.000227	CcSEcCtD
Temsirolimus—Rash—Cisplatin—lung cancer	2.04e-05	0.000226	CcSEcCtD
Temsirolimus—Dermatitis—Cisplatin—lung cancer	2.04e-05	0.000226	CcSEcCtD
Temsirolimus—Diarrhoea—Etoposide—lung cancer	2.03e-05	0.000225	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—lung cancer	2.02e-05	0.000224	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Docetaxel—lung cancer	2.02e-05	0.000224	CcSEcCtD
Temsirolimus—Anaemia—Methotrexate—lung cancer	2.01e-05	0.000223	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—lung cancer	2.01e-05	0.000223	CcSEcCtD
Temsirolimus—Diarrhoea—Paclitaxel—lung cancer	1.99e-05	0.000221	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—lung cancer	1.97e-05	0.000218	CcSEcCtD
Temsirolimus—Dizziness—Etoposide—lung cancer	1.96e-05	0.000218	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—lung cancer	1.96e-05	0.000217	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—lung cancer	1.95e-05	0.000216	CcSEcCtD
Temsirolimus—Abdominal pain—Docetaxel—lung cancer	1.95e-05	0.000216	CcSEcCtD
Temsirolimus—Body temperature increased—Docetaxel—lung cancer	1.95e-05	0.000216	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—lung cancer	1.95e-05	0.000216	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—lung cancer	1.94e-05	0.000216	CcSEcCtD
Temsirolimus—Dizziness—Paclitaxel—lung cancer	1.92e-05	0.000213	CcSEcCtD
Temsirolimus—Nausea—Cisplatin—lung cancer	1.92e-05	0.000213	CcSEcCtD
Temsirolimus—Cough—Methotrexate—lung cancer	1.9e-05	0.000211	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—lung cancer	1.9e-05	0.00021	CcSEcCtD
Temsirolimus—Convulsion—Methotrexate—lung cancer	1.89e-05	0.000209	CcSEcCtD
Temsirolimus—Vomiting—Etoposide—lung cancer	1.89e-05	0.000209	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—lung cancer	1.89e-05	0.000209	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—lung cancer	1.89e-05	0.000209	CcSEcCtD
Temsirolimus—Rash—Etoposide—lung cancer	1.87e-05	0.000207	CcSEcCtD
Temsirolimus—Dermatitis—Etoposide—lung cancer	1.87e-05	0.000207	CcSEcCtD
Temsirolimus—Headache—Etoposide—lung cancer	1.86e-05	0.000206	CcSEcCtD
Temsirolimus—Arthralgia—Methotrexate—lung cancer	1.85e-05	0.000206	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—lung cancer	1.85e-05	0.000206	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—lung cancer	1.85e-05	0.000206	CcSEcCtD
Temsirolimus—Vomiting—Paclitaxel—lung cancer	1.85e-05	0.000205	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—lung cancer	1.85e-05	0.000205	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.84e-05	0.000204	CcSEcCtD
Temsirolimus—Rash—Paclitaxel—lung cancer	1.83e-05	0.000203	CcSEcCtD
Temsirolimus—Dermatitis—Paclitaxel—lung cancer	1.83e-05	0.000203	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—lung cancer	1.82e-05	0.000202	CcSEcCtD
Temsirolimus—Headache—Paclitaxel—lung cancer	1.82e-05	0.000202	CcSEcCtD
Temsirolimus—Hypersensitivity—Docetaxel—lung cancer	1.82e-05	0.000201	CcSEcCtD
Temsirolimus—Anaphylactic shock—Methotrexate—lung cancer	1.78e-05	0.000197	CcSEcCtD
Temsirolimus—Asthenia—Docetaxel—lung cancer	1.77e-05	0.000196	CcSEcCtD
Temsirolimus—Infection—Methotrexate—lung cancer	1.77e-05	0.000196	CcSEcCtD
Temsirolimus—Nausea—Etoposide—lung cancer	1.76e-05	0.000195	CcSEcCtD
Temsirolimus—Pruritus—Docetaxel—lung cancer	1.74e-05	0.000193	CcSEcCtD
Temsirolimus—Nervous system disorder—Methotrexate—lung cancer	1.74e-05	0.000193	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—lung cancer	1.74e-05	0.000193	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—lung cancer	1.74e-05	0.000193	CcSEcCtD
Temsirolimus—Nausea—Paclitaxel—lung cancer	1.73e-05	0.000192	CcSEcCtD
Temsirolimus—Skin disorder—Methotrexate—lung cancer	1.73e-05	0.000191	CcSEcCtD
Temsirolimus—Anorexia—Methotrexate—lung cancer	1.69e-05	0.000188	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—lung cancer	1.69e-05	0.000187	CcSEcCtD
Temsirolimus—Diarrhoea—Docetaxel—lung cancer	1.69e-05	0.000187	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—lung cancer	1.65e-05	0.000182	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—lung cancer	1.63e-05	0.000181	CcSEcCtD
Temsirolimus—Dizziness—Docetaxel—lung cancer	1.63e-05	0.000181	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—lung cancer	1.63e-05	0.000181	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—lung cancer	1.62e-05	0.00018	CcSEcCtD
Temsirolimus—Insomnia—Methotrexate—lung cancer	1.61e-05	0.000178	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—lung cancer	1.61e-05	0.000178	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—lung cancer	1.61e-05	0.000178	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—lung cancer	1.61e-05	0.000178	CcSEcCtD
Temsirolimus—Anxiety—Doxorubicin—lung cancer	1.6e-05	0.000177	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.59e-05	0.000177	CcSEcCtD
Temsirolimus—Dyspnoea—Methotrexate—lung cancer	1.58e-05	0.000176	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—lung cancer	1.58e-05	0.000175	CcSEcCtD
Temsirolimus—Vomiting—Docetaxel—lung cancer	1.57e-05	0.000174	CcSEcCtD
Temsirolimus—Rash—Docetaxel—lung cancer	1.55e-05	0.000172	CcSEcCtD
Temsirolimus—Dermatitis—Docetaxel—lung cancer	1.55e-05	0.000172	CcSEcCtD
Temsirolimus—Decreased appetite—Methotrexate—lung cancer	1.55e-05	0.000171	CcSEcCtD
Temsirolimus—Headache—Docetaxel—lung cancer	1.54e-05	0.000171	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—lung cancer	1.54e-05	0.000171	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—lung cancer	1.54e-05	0.000171	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Methotrexate—lung cancer	1.53e-05	0.00017	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—lung cancer	1.53e-05	0.00017	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—lung cancer	1.53e-05	0.00017	CcSEcCtD
Temsirolimus—Pain—Methotrexate—lung cancer	1.52e-05	0.000169	CcSEcCtD
Temsirolimus—Nervous system disorder—Doxorubicin—lung cancer	1.51e-05	0.000167	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—lung cancer	1.51e-05	0.000167	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—lung cancer	1.49e-05	0.000166	CcSEcCtD
Temsirolimus—Anorexia—Doxorubicin—lung cancer	1.47e-05	0.000163	CcSEcCtD
Temsirolimus—Nausea—Docetaxel—lung cancer	1.46e-05	0.000162	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Methotrexate—lung cancer	1.45e-05	0.000161	CcSEcCtD
Temsirolimus—Abdominal pain—Methotrexate—lung cancer	1.41e-05	0.000156	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—lung cancer	1.41e-05	0.000156	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.4e-05	0.000155	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—lung cancer	1.39e-05	0.000154	CcSEcCtD
Temsirolimus—Dyspnoea—Doxorubicin—lung cancer	1.37e-05	0.000152	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—lung cancer	1.37e-05	0.000152	CcSEcCtD
Temsirolimus—Decreased appetite—Doxorubicin—lung cancer	1.34e-05	0.000148	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—lung cancer	1.33e-05	0.000147	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—lung cancer	1.33e-05	0.000147	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—lung cancer	1.32e-05	0.000146	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—lung cancer	1.32e-05	0.000146	CcSEcCtD
Temsirolimus—Hypersensitivity—Methotrexate—lung cancer	1.31e-05	0.000145	CcSEcCtD
Temsirolimus—Asthenia—Methotrexate—lung cancer	1.28e-05	0.000141	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Doxorubicin—lung cancer	1.26e-05	0.00014	CcSEcCtD
Temsirolimus—Pruritus—Methotrexate—lung cancer	1.26e-05	0.000139	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—lung cancer	1.22e-05	0.000135	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—lung cancer	1.22e-05	0.000135	CcSEcCtD
Temsirolimus—Diarrhoea—Methotrexate—lung cancer	1.22e-05	0.000135	CcSEcCtD
Temsirolimus—Dizziness—Methotrexate—lung cancer	1.18e-05	0.00013	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—lung cancer	1.13e-05	0.000126	CcSEcCtD
Temsirolimus—Vomiting—Methotrexate—lung cancer	1.13e-05	0.000125	CcSEcCtD
Temsirolimus—Rash—Methotrexate—lung cancer	1.12e-05	0.000124	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—lung cancer	1.12e-05	0.000124	CcSEcCtD
Temsirolimus—Headache—Methotrexate—lung cancer	1.11e-05	0.000123	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—lung cancer	1.1e-05	0.000122	CcSEcCtD
Temsirolimus—Pruritus—Doxorubicin—lung cancer	1.09e-05	0.000121	CcSEcCtD
Temsirolimus—Nausea—Methotrexate—lung cancer	1.06e-05	0.000117	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—lung cancer	1.05e-05	0.000117	CcSEcCtD
Temsirolimus—Dizziness—Doxorubicin—lung cancer	1.02e-05	0.000113	CcSEcCtD
Temsirolimus—Vomiting—Doxorubicin—lung cancer	9.79e-06	0.000108	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—lung cancer	9.7e-06	0.000108	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—lung cancer	9.69e-06	0.000107	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—lung cancer	9.64e-06	0.000107	CcSEcCtD
Temsirolimus—Nausea—Doxorubicin—lung cancer	9.14e-06	0.000101	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—PIK3CA—lung cancer	3.21e-06	5.72e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TERT—lung cancer	3.2e-06	5.7e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PIK3CA—lung cancer	3.2e-06	5.69e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CB—lung cancer	3.19e-06	5.69e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MMP9—lung cancer	3.19e-06	5.68e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD4—lung cancer	3.19e-06	5.68e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1A—lung cancer	3.18e-06	5.66e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTEN—lung cancer	3.17e-06	5.65e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NCOA3—lung cancer	3.17e-06	5.65e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FGFR1—lung cancer	3.1e-06	5.53e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—lung cancer	3.09e-06	5.51e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ABCG2—lung cancer	3.08e-06	5.49e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ADCY1—lung cancer	3.08e-06	5.49e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALDOA—lung cancer	3.08e-06	5.48e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP2A7—lung cancer	3.07e-06	5.48e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HIF1A—lung cancer	3.06e-06	5.45e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MDM2—lung cancer	3.03e-06	5.4e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EP300—lung cancer	3.02e-06	5.39e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO2—lung cancer	3.02e-06	5.39e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HPGDS—lung cancer	3.02e-06	5.39e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—RAF1—lung cancer	3.02e-06	5.38e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SDC4—lung cancer	3.01e-06	5.36e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PPP2R1B—lung cancer	3e-06	5.35e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—lung cancer	2.99e-06	5.32e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NCOA3—lung cancer	2.99e-06	5.32e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—lung cancer	2.97e-06	5.29e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—IL6—lung cancer	2.96e-06	5.27e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—lung cancer	2.96e-06	5.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—APOA1—lung cancer	2.95e-06	5.26e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CB—lung cancer	2.95e-06	5.25e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CD4—lung cancer	2.94e-06	5.24e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SRC—lung cancer	2.94e-06	5.24e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTT1—lung cancer	2.93e-06	5.22e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL2—lung cancer	2.93e-06	5.22e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KDR—lung cancer	2.92e-06	5.21e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—lung cancer	2.92e-06	5.2e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—STK11—lung cancer	2.91e-06	5.19e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ABCG2—lung cancer	2.91e-06	5.18e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ADCY1—lung cancer	2.91e-06	5.18e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GCLC—lung cancer	2.9e-06	5.16e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP2A6—lung cancer	2.9e-06	5.16e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—lung cancer	2.86e-06	5.1e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—JUN—lung cancer	2.85e-06	5.08e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HPGDS—lung cancer	2.85e-06	5.08e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO2—lung cancer	2.85e-06	5.08e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	2.85e-06	5.07e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—STAT3—lung cancer	2.84e-06	5.05e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PPP2R1B—lung cancer	2.83e-06	5.04e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—lung cancer	2.83e-06	5.04e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—IL6—lung cancer	2.83e-06	5.04e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—APOA1—lung cancer	2.79e-06	4.96e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1A—lung cancer	2.77e-06	4.93e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTT1—lung cancer	2.76e-06	4.92e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTEN—lung cancer	2.76e-06	4.92e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO1—lung cancer	2.75e-06	4.9e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	2.75e-06	4.89e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA3—lung cancer	2.74e-06	4.88e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—RRM1—lung cancer	2.74e-06	4.88e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GCLC—lung cancer	2.73e-06	4.87e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP2A6—lung cancer	2.73e-06	4.87e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—lung cancer	2.73e-06	4.86e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK3—lung cancer	2.71e-06	4.83e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIT—lung cancer	2.69e-06	4.8e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CG—lung cancer	2.69e-06	4.8e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—APC—lung cancer	2.69e-06	4.8e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTP1—lung cancer	2.69e-06	4.8e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGF—lung cancer	2.66e-06	4.74e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—lung cancer	2.64e-06	4.7e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EP300—lung cancer	2.63e-06	4.69e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—lung cancer	2.62e-06	4.67e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CAT—lung cancer	2.62e-06	4.67e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—lung cancer	2.61e-06	4.65e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO1—lung cancer	2.59e-06	4.61e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—lung cancer	2.58e-06	4.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—B4GALT5—lung cancer	2.58e-06	4.59e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	2.57e-06	4.58e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—POMC—lung cancer	2.56e-06	4.57e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—SRC—lung cancer	2.56e-06	4.56e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1A—lung cancer	2.55e-06	4.55e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ABCB1—lung cancer	2.55e-06	4.54e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—lung cancer	2.55e-06	4.54e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CG—lung cancer	2.54e-06	4.53e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—BRAF—lung cancer	2.53e-06	4.51e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA4—lung cancer	2.51e-06	4.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TYMS—lung cancer	2.5e-06	4.46e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL6R—lung cancer	2.5e-06	4.46e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CREBBP—lung cancer	2.5e-06	4.45e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTM1—lung cancer	2.48e-06	4.41e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—STAT3—lung cancer	2.47e-06	4.4e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP2E1—lung cancer	2.46e-06	4.39e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—lung cancer	2.46e-06	4.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA2—lung cancer	2.44e-06	4.35e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NQO1—lung cancer	2.44e-06	4.34e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—lung cancer	2.44e-06	4.34e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EP300—lung cancer	2.43e-06	4.33e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—POMC—lung cancer	2.42e-06	4.31e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAP2K1—lung cancer	2.38e-06	4.25e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CD—lung cancer	2.37e-06	4.22e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SRC—lung cancer	2.36e-06	4.21e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CREBBP—lung cancer	2.36e-06	4.2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK3—lung cancer	2.36e-06	4.2e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA1—lung cancer	2.36e-06	4.2e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP1A1—lung cancer	2.35e-06	4.18e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCC3—lung cancer	2.33e-06	4.15e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ERCC2—lung cancer	2.33e-06	4.15e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	2.32e-06	4.14e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP2E1—lung cancer	2.32e-06	4.14e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NQO1—lung cancer	2.3e-06	4.09e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—STAT3—lung cancer	2.28e-06	4.06e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—lung cancer	2.27e-06	4.05e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKR1C1—lung cancer	2.26e-06	4.02e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—lung cancer	2.24e-06	4e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CA—lung cancer	2.24e-06	3.99e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CD—lung cancer	2.24e-06	3.98e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ALB—lung cancer	2.21e-06	3.93e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—STK11—lung cancer	2.2e-06	3.91e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—UGT1A1—lung cancer	2.19e-06	3.9e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAPK3—lung cancer	2.18e-06	3.88e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—lung cancer	2.16e-06	3.86e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MDM2—lung cancer	2.12e-06	3.78e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—lung cancer	2.12e-06	3.77e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—lung cancer	2.12e-06	3.77e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RAF1—lung cancer	2.11e-06	3.77e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GNG11—lung cancer	2.11e-06	3.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—lung cancer	2.09e-06	3.73e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—lung cancer	2.07e-06	3.69e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—STK11—lung cancer	2.07e-06	3.69e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—lung cancer	2.07e-06	3.69e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CB—lung cancer	2.06e-06	3.68e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTP1—lung cancer	2.03e-06	3.62e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—APOA1—lung cancer	2.01e-06	3.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALDOA—lung cancer	2.01e-06	3.58e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCL8—lung cancer	1.98e-06	3.53e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL6—lung cancer	1.98e-06	3.53e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CAT—lung cancer	1.98e-06	3.52e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—lung cancer	1.96e-06	3.48e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NCOA3—lung cancer	1.95e-06	3.48e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CB—lung cancer	1.95e-06	3.47e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CA—lung cancer	1.95e-06	3.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—lung cancer	1.93e-06	3.44e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTP1—lung cancer	1.92e-06	3.41e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCG2—lung cancer	1.9e-06	3.38e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ADCY1—lung cancer	1.9e-06	3.38e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CASP3—lung cancer	1.9e-06	3.38e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL2—lung cancer	1.9e-06	3.38e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TYMS—lung cancer	1.89e-06	3.37e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTM1—lung cancer	1.87e-06	3.33e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CAT—lung cancer	1.86e-06	3.32e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HPGDS—lung cancer	1.86e-06	3.32e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO2—lung cancer	1.86e-06	3.32e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.85e-06	3.3e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—lung cancer	1.85e-06	3.29e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JUN—lung cancer	1.84e-06	3.29e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CG—lung cancer	1.84e-06	3.27e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—lung cancer	1.83e-06	3.26e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ABCB1—lung cancer	1.81e-06	3.23e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTT1—lung cancer	1.81e-06	3.22e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—lung cancer	1.8e-06	3.21e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CA—lung cancer	1.8e-06	3.2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MMP9—lung cancer	1.79e-06	3.2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1A—lung cancer	1.79e-06	3.19e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GCLC—lung cancer	1.79e-06	3.18e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP2A6—lung cancer	1.79e-06	3.18e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—lung cancer	1.78e-06	3.18e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TYMS—lung cancer	1.78e-06	3.17e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP1A1—lung cancer	1.77e-06	3.15e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTM1—lung cancer	1.76e-06	3.14e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ERCC2—lung cancer	1.76e-06	3.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—POMC—lung cancer	1.75e-06	3.12e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL6—lung cancer	1.72e-06	3.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CREBBP—lung cancer	1.7e-06	3.04e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EP300—lung cancer	1.7e-06	3.03e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO1—lung cancer	1.69e-06	3.02e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—lung cancer	1.68e-06	3e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP1A1—lung cancer	1.67e-06	2.97e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—lung cancer	1.66e-06	2.96e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ERCC2—lung cancer	1.66e-06	2.95e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SRC—lung cancer	1.65e-06	2.95e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CD—lung cancer	1.62e-06	2.88e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—lung cancer	1.61e-06	2.87e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—EP300—lung cancer	1.61e-06	2.86e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STAT3—lung cancer	1.6e-06	2.84e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ALB—lung cancer	1.6e-06	2.84e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—lung cancer	1.59e-06	2.84e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—IL6—lung cancer	1.59e-06	2.83e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—lung cancer	1.59e-06	2.83e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK3—lung cancer	1.52e-06	2.72e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—APOA1—lung cancer	1.52e-06	2.71e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP2E1—lung cancer	1.52e-06	2.71e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NQO1—lung cancer	1.5e-06	2.68e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—lung cancer	1.48e-06	2.64e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—lung cancer	1.47e-06	2.62e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—lung cancer	1.45e-06	2.58e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—APOA1—lung cancer	1.43e-06	2.55e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CB—lung cancer	1.41e-06	2.51e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—lung cancer	1.4e-06	2.49e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CG—lung cancer	1.39e-06	2.47e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—lung cancer	1.37e-06	2.44e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—STK11—lung cancer	1.35e-06	2.41e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—POMC—lung cancer	1.32e-06	2.35e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CG—lung cancer	1.31e-06	2.33e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CREBBP—lung cancer	1.29e-06	2.29e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CA—lung cancer	1.26e-06	2.24e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTP1—lung cancer	1.25e-06	2.23e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—POMC—lung cancer	1.24e-06	2.22e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CD—lung cancer	1.22e-06	2.17e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CAT—lung cancer	1.22e-06	2.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—lung cancer	1.22e-06	2.17e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—lung cancer	1.22e-06	2.17e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CREBBP—lung cancer	1.21e-06	2.16e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALB—lung cancer	1.2e-06	2.14e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CA—lung cancer	1.19e-06	2.12e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCB1—lung cancer	1.19e-06	2.11e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TYMS—lung cancer	1.16e-06	2.07e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—lung cancer	1.16e-06	2.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—EP300—lung cancer	1.16e-06	2.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTM1—lung cancer	1.15e-06	2.05e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CD—lung cancer	1.15e-06	2.05e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALB—lung cancer	1.13e-06	2.02e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL6—lung cancer	1.11e-06	1.99e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP1A1—lung cancer	1.09e-06	1.94e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ERCC2—lung cancer	1.08e-06	1.93e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CB—lung cancer	1.06e-06	1.89e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—lung cancer	1.05e-06	1.88e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—lung cancer	1.03e-06	1.83e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CB—lung cancer	1e-06	1.78e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—lung cancer	9.92e-07	1.77e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—lung cancer	9.7e-07	1.73e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—APOA1—lung cancer	9.36e-07	1.67e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—lung cancer	9.18e-07	1.64e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—EP300—lung cancer	8.76e-07	1.56e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—lung cancer	8.65e-07	1.54e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CA—lung cancer	8.59e-07	1.53e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CG—lung cancer	8.55e-07	1.52e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—EP300—lung cancer	8.25e-07	1.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—POMC—lung cancer	8.13e-07	1.45e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CREBBP—lung cancer	7.92e-07	1.41e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CD—lung cancer	7.51e-07	1.34e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALB—lung cancer	7.42e-07	1.32e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—lung cancer	7.01e-07	1.25e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CB—lung cancer	6.55e-07	1.17e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—lung cancer	6.49e-07	1.16e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CA—lung cancer	6.48e-07	1.15e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CA—lung cancer	6.11e-07	1.09e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—lung cancer	5.66e-07	1.01e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—EP300—lung cancer	5.4e-07	9.61e-06	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—lung cancer	5.29e-07	9.43e-06	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—lung cancer	4.99e-07	8.89e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CA—lung cancer	3.99e-07	7.11e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—lung cancer	3.26e-07	5.81e-06	CbGpPWpGaD
